Dr Eduardo Cazap speaks to Dr Lisa Stevens at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting for ecancer's Global Cancer Leaders initiative. They discuss the position of global and international leaders in determining the future of...
Mon Jun 24, 2019 17:24
Eduardo Cazap, MD, PhD speaks to Prof Tezer Kutluk at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting for ecancer's Global Cancer Leaders initiative. They begin by discussing why cancer cases are still increasing despite better...
Fri Jun 21, 2019 15:41
Eduardo Cazap, MD, PhD speaks to Dr Clifford Hudis at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting for ecancer's Global Cancer Leaders initiative. They begin by discussing a stepwise program to address the increasing demand of...
Fri Jun 21, 2019 15:38
Eduardo Cazap, MD, PhD speaks to Dr Richard Schilsky at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting for ecancer's Global Cancer Leaders initiative. They initially tackle the issue of global cancer care, and how ASCO aims to help...
Fri Jun 21, 2019 15:35
Prof Robin Foa speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about treatment alternatives to chemotherapy for leukaemia. He explains that today there are many targeted treatments that are succesful, particularly with...
Thu Jun 20, 2019 18:25
Prof Robin Foa speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the combination of dasatinib and blinatumomab for the front-line treatment of adult Ph-positive acute lymphoblastic leukaemia (ALL). He explains that...
Thu Jun 20, 2019 18:22
Prof Max Topp speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about a dose escalation trial in patients with relapsed and refractory B-cell non-hodgkin lymphoma using REGN1979 - an anti-CD20 x anti-CD3 bispecific...
Thu Jun 20, 2019 18:05
Prof Alexander Perl speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the updated results from the AMIRAL study looking at the use of gilteritinib versus salvage chemotherapy in patients with FLT3-mutated...
Thu Jun 20, 2019 18:05
Prof Mohamad Mohty speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about what is being discussed in multiple myeloma at EHA 2019. He believes that the use of monoclonal antibodies have been a real highlight from this...
Thu Jun 20, 2019 18:04
Dr Michaela Kotrova speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting the poster she was presenting on acute lymphoblastic leukaemia patients who were treated with CD19-directed immunotherapies. She explains that by...
Thu Jun 20, 2019 18:03
Prof Mohamad Mohty speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the promising CAR T-cell therapy for acute leukaemia patients. He explains that a substantial proportion of acute lymphocytic leukaemia and...
Thu Jun 20, 2019 18:03
Prof Walter Fiedler speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about a phase II study looking at the use of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. He...
Thu Jun 20, 2019 18:01
Dr Heng Mei speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about improving the safety of CAR T-cell therapy by controlling CRS-related coagulopathy. He reports that the phase I study found that early and proper...
Thu Jun 20, 2019 18:00
Dr Andrea Gallamini speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the 3 year update from the ECHELON-1 study into frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma. He...
Thu Jun 20, 2019 18:00
Michael Fuchs speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about research looking at PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma treated within the phase III GHSG HD16...
Thu Jun 20, 2019 17:58
Prof Paul Richardson speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the results of the ICARIA trial. The phase III trial used isatuximab, pomalidomide and low-dose dexamethasone vs pomalidomide and low-dose...
Thu Jun 20, 2019 17:44
HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide
Prof Paul Richardson speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the updated results of the HORIZON trial. Preliminary results were presented at the meeting regarding the efficacy and safety of melflufen in...
Thu Jun 20, 2019 17:42
Dr Mark Roschewski speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting on the phase IB/2 results of a study evaluating the safety and efficacy of escalating doses of the first-in-class anti-CD47 antibody Hu5F9-G4 with...
Thu Jun 20, 2019 17:40
Dr Ashkan Emadi speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about a study looking at the combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia He explains that after conducting robust mechanisms...
Thu Jun 20, 2019 17:38
Prof Heinz-Josef Lenz talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the POLO III trail, and his opinion on the findings. He explains an outline of the trial, including some of. the many benefits to using a...
Thu Jun 13, 2019 18:15
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου